22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation

      , , , ,
      Journal of Pharmaceutical and Biomedical Analysis
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A simple and accurate liquid chromatographic method was developed and validated for estimation of isoniazid (ISN), pyrazinamide (PYR) and rifampicin (RIF) in combined dosage forms. Drugs were chromatographed on a reverse phase C18 column using a mobile phase gradient and monitored at the corresponding maximum of each compounds. Peaks were identified with retention time as compared with standards and confirmed with characteristic spectra using diode-array detector. Solution concentrations were measured on a weight basis to avoid the use of an internal standard. The method does not require any specific sample preparation except the use of a guard column. The method is linear (r(2)>0.999), precise (RSD%: 0.50% for ISN, 0.12% for PYR and 0.98% for RIF), accurate (overall average recovery yields: 98.55% for ISN, 98.51 for PYR and 98.56% for RIF) and selective. Due to its simplicity and accuracy the method is suitable for routine quality control analysis of antitubercolosis combination dosage form.

          Related collections

          Author and article information

          Journal
          Journal of Pharmaceutical and Biomedical Analysis
          Journal of Pharmaceutical and Biomedical Analysis
          Elsevier BV
          07317085
          August 2002
          August 2002
          : 29
          : 6
          : 1089-1096
          Article
          10.1016/S0731-7085(02)00150-4
          12110394
          8b067301-765a-4ebb-ae82-6df86897af47
          © 2002

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article